StemCell Therapy

New York, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gene Therapy Industry" - https://www.reportlinker.com/p05817594/?utm_source=GNW 6% in the year 2020 and thereafter recover and grow to reach US$3.3 billion by the year 2027, trailing a post COVID-19 CAGR of 19.5% over the analysis period 2020 through 2027. Governments worldwide are focusing all healthcare resources on fighting the global pandemic. Billions of dollars have poured into researching COVID-19 drugs, therapies and vaccines. Over US$8 billion globally excluding the U.S. has been pledged only for vaccine development. The U.S. has independently pumped billions of dollars into COVID-19 research and response. The massive reallocation of funds and reprioritization of efforts has left a glaring gap in other sectors of healthcare. Gene therapy which holds promise for treating cancer, cystic fibrosis, heart disease, diabetes, hemophilia & AIDS, is slumping due to lack of research funds & reduced footfall of patients seeking treatment. Given the complex and fragile manufacturing and delivery system along with funding models of the industry, COVID-19 has emerged as a black swan event. Various players still find it challenging to ensure timely delivery of gene therapy to patients and clinical sites. There are concerns regarding administration of cell and gene therapies. The chances of virus transmission, mainly to people in the high-risk group, coerced hospitals to delay or cancel appointments. In addition, travel restrictions and stay-at-home orders discouraged patients from visiting to treatment centres. Treatments intended to be delivered into ICUs are being impacted by bed reservations made for patients with COVID-19 infection.

R&D and preclinical activities are also affected by supply shortages as a result of strong demand for consumables like reagents and PPE from COVID-19 laboratories. The clinical development segment suffered the most due to concerns regarding recruitment of patients and suspension of trial enrolments for protecting participants from the risk of infection. These issues are delaying activation of new sites, prompting players to postpone new clinical trials. However, the intensity of disruptions for cell and gene therapy trials was less in comparison to the pharmaceutical industry due to association of the former with rare and serious medical conditions, enabling participants to continue trials. While companies targeting paediatric diseases suspended trials, others dealing with oncology maintained the pace. COVID-19 has also impacted patient assessment and has made it difficult for companies to perform follow-up evaluations for trial participants. These issues are attributed to confluence of various factors like travel ban, withdrawal of several services from healthcare sites and the risk of virus transmission. In addition, these disruptions are anticipated to threaten existence of certain cell and gene therapy companies, particularly small-scale biotech players that are in pre-commercial phase and rely on external funding. As governments, stakeholders, pharmaceutical companies and venture capitalists invest in these players on the basis of research milestones, pipeline progress and data readouts, ability of these companies to secure future funding will also be affected.

In the post COVID-19 period, growth will be led by therapy indications in the field of oncology. Gene therapies hold promise to improve the condition of patients where traditional cancer treatments such as radiation and chemotherapy are not effective. Blood and lymphatic cancers hold huge potential as gene therapies can manipulate the genetic information to target the cancerous proteins, thereby enabling the body to fight against the cancers. Oncology will remain the key area of focus for gene therapy applications. Cancer therapies represent the leading category, as is gauged through robust rise in the number of molecules being tested across numerous clinical trials. Novartis which recently bagged the U.S. FDA approval for Kymriah, a gene therapy designed for the treatment of hematological cancer, is seeking to gain commercial approval in established and emerging countries. Similarly, Kite Pharma, the developer of YESCARTA, the first CAR T-cell therapy approved for certain types of non-Hodgkin lymphoma in adults, has formed a separate team to provide end-to-end support for its Yescarta customers including hospitals and clinics. Such efforts by developers would augment the use case of gene therapies in treatment of large B-cell lymphoma and acute lymphoblastic leukemia (ALL), the high potential cancer treatment verticals. More developmental focus will also be shed on monogenic rare diseases which have clearer genomic targets and the unmet need in smaller patient populations. Majority gene therapies so far have come to market through accelerated review pathways of regulatory authorities. In the year 2018 alone, over 150 applications for investigational new drugs for gene therapies were filed. In the coming years, there will be significant improvement in the number of approvals for new gene therapies. The growth is anticipated to emerge from different modalities including RNAi, ASOs and CRISPR gene editing based therapeutics which offer long term opportunities for growth. These technologies are generating much excitement for investors.

Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05817594/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1 A Prelude to Gene Therapy II-1 Classification of Gene Therapies II-1 Impact of Covid-19 and a Looming Global Recession II-2 COVID-19 Causes Gene Therapy Market to Buckle & Collapse II-2 COVID-19 Impact on Different Aspects of Gene Therapy II-2 Manufacturing & Delivery II-2 Research & Clinical Development II-3 Commercial Operations & Access II-3 Managing Derailed Operations II-4 Focus on Clinical Development Programs II-4 Targeting Manufacturing & Delivery Strategies II-4 Securing Supplies II-4 Remote Working II-4 Gene Therapy Set to Witness Rapid Growth Post COVID-19 II-5 By Vector Type II-5 VIRAL VECTORS ACCOUNT FOR A MAJOR SHARE OF THE MARKET II-5 Adeno-Associated Virus Vectors II-6 Lentivirus II-6 NON-VIRAL VECTORS TO WITNESS FASTER GROWTH II-7 US and Europe Dominate the Gene Therapy Market II-8 Oncology Represents the Largest Indication for Gene Therapy II-9 Market Outlook II-9 WORLD BRANDS II-10

2. FOCUS ON SELECT PLAYERS II-16 Recent Market Activity II-18 Select Innovations II-24

3. MARKET TRENDS & DRIVERS II-25 Availability of Novel Therapies Drive Market Growth II-25 Select Approved Gene Therapy Products II-26 Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy II-27 Lentiviral Vectors Witness Increased Interest II-27 Rising Cancer Incidence Worldwide Spurs Demand for Gene Therapy II-28 Exhibit 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-28 Exhibit 2: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018 II-29 Exhibit 3: Number of New Cancer Cases and Deaths (in Million) by Region for 2018 II-30 Compelling Level of Technology & Innovation to Ignite Gene Therapy II-30 Promising Gene Therapy Innovations for Treatment of Inherited Retinal Diseases II-31 Gene Therapy Pivots M&A Activity in Dynamic Domain of Genomic Medicine II-31 M&As Rampant in Gene Therapy Space II-31 Gene Therapy Deals: 2018 and 2019 II-32 Emphasis on Formulating Robust Regulatory Framework II-33 Strong Gene Therapy Pipeline II-33 Gene Therapy: Phase III Clinical Trials II-33 OHSU Implements First-Ever LCA10 Gene Therapy Clinical Trial with CRISPR II-35 Growing Funding for Gene Therapy Research II-35 Market Issues & Challenges II-35

4. GLOBAL MARKET PERSPECTIVE II-37 Table 1: World Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-37

Table 2: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-38

Table 3: World 10-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2017, 2020 & 2027 II-39

Table 4: World Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-40

Table 5: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-41

Table 6: World 10-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-42

Table 7: World Current & Future Analysis for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-43

Table 8: World Historic Review for Non-Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-44

Table 9: World 10-Year Perspective for Non-Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-45

Table 10: World Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-46

Table 11: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-47

Table 12: World 10-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-48

Table 13: World Current & Future Analysis for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-49

Table 14: World Historic Review for Rare Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-50

Table 15: World 10-Year Perspective for Rare Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-51

Table 16: World Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-52

Table 17: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-53

Table 18: World 10-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-54

Table 19: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 II-55

Table 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 II-56

Table 21: World 10-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2017, 2020 & 2027 II-57

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1 Table 22: USA Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-1

Table 23: USA Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-2

Table 24: USA 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-3

Table 25: USA Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-4

Table 26: USA Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-5

Table 27: USA 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-6

CANADA III-7 Table 28: Canada Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-7

Table 29: Canada Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-8

Table 30: Canada 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-9

Table 31: Canada Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-10

Table 32: Canada Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-11

Table 33: Canada 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-12

JAPAN III-13 Table 34: Japan Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-13

Table 35: Japan Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-14

Table 36: Japan 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-15

Table 37: Japan Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-16

Table 38: Japan Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-17

Table 39: Japan 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-18

CHINA III-19 Table 40: China Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-19

Table 41: China Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-20

Table 42: China 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-21

Table 43: China Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-22

Table 44: China Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-23

Table 45: China 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-24

EUROPE III-25 Table 46: Europe Current & Future Analysis for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 III-25

Table 47: Europe Historic Review for Gene Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-26

Table 48: Europe 10-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2017, 2020 & 2027 III-27

Table 49: Europe Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-28

Table 50: Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-29

Table 51: Europe 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-30

Table 52: Europe Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-31

Table 53: Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-32

Table 54: Europe 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-33

FRANCE III-34 Table 55: France Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-34

Table 56: France Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-35

Table 57: France 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-36

Table 58: France Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-37

Table 59: France Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-38

Table 60: France 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-39

GERMANY III-40 Table 61: Germany Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-40

Table 62: Germany Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-41

Table 63: Germany 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-42

Table 64: Germany Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-43

Table 65: Germany Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-44

Table 66: Germany 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-45

ITALY III-46 Table 67: Italy Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-46

Table 68: Italy Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-47

Table 69: Italy 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-48

Table 70: Italy Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-49

Table 71: Italy Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-50

Table 72: Italy 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-51

UNITED KINGDOM III-52 Table 73: UK Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-52

Table 74: UK Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-53

Table 75: UK 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-54

Table 76: UK Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-55

Table 77: UK Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-56

Table 78: UK 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-57

REST OF EUROPE III-58 Table 79: Rest of Europe Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-58

Table 80: Rest of Europe Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-59

Table 81: Rest of Europe 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-60

Table 82: Rest of Europe Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-61

Table 83: Rest of Europe Historic Review for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-62

Table 84: Rest of Europe 10-Year Perspective for Gene Therapy by Application - Percentage Breakdown of Value Sales for Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications for the Years 2017, 2020 & 2027 III-63

ASIA-PACIFIC III-64 Table 85: Asia-Pacific Current & Future Analysis for Gene Therapy by Vector Type - Viral and Non-Viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-64

Table 86: Asia-Pacific Historic Review for Gene Therapy by Vector Type - Viral and Non-Viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2017 through 2019 III-65

Table 87: Asia-Pacific 10-Year Perspective for Gene Therapy by Vector Type - Percentage Breakdown of Value Sales for Viral and Non-Viral for the Years 2017, 2020 & 2027 III-66

Table 88: Asia-Pacific Current & Future Analysis for Gene Therapy by Application - Oncological Disorders, Rare Diseases, Neurological Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 III-67

See original here:
Global Gene Therapy Industry - GlobeNewswire

NEW YORKand RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced the appointment of Guangping Gao, Ph.D., as Chief AAV Scientific Advisor. Dr. Gao, a world-recognized scientist and past President of the ASGCT, has played key roles in the discovery and characterization of adeno-associated virus (AAV) serotypes which were instrumental in the resurgence of gene therapy. In his advisory role, Dr. Gao will provide strategic guidance and scientific and technical input across Sios AAV-based gene therapy programs.

We are honored to welcome Dr. Gao, a gene therapy pioneer, to Sio Gene Therapies, said Pavan Cheruvu, M.D., Chief Executive Officer ofSio. Dr. Gao brings an incredible wealth of knowledge ranging from fundamental discoveries in viral vectors, preclinical and clinical gene therapy product development, to viral manufacturing for clinical research. We believe his experience and insight will be invaluable to our team as we continue to advance our pipeline and evaluate potential business development opportunities. We look forward to collaborating with Dr. Gao as we work toward our mission of providing transformative treatments to patients with severe genetic disease.

Dr. Gao said, Sios strategic approach to gene therapy directly targets the underlying disease biology, which I believe has the potential to lead to transformative and life-saving treatments. I have been impressed by the teams comprehensive execution in driving forward clinical programs while in parallel laying a strong manufacturing foundation to support their mission to deliver these treatments to patients as rapidly as possible. I am thrilled to begin my role at Sio and look forward to leveraging my diverse experiences to fully unlock the potential of their gene therapy portfolio."

Dr. Gao is Co-Director of the Li Weibo Institute for Rare Disease Research, Director of the Horae Gene Therapy Center and Viral Vector Core, Professor of Microbiology and Physiological Systems and Penelope Booth Rockwell Professor in Biomedical Research at the University of Massachusetts Medical School. Dr Gaos more than 30 years in scientific research in molecular genetics have made foundational contributions to the development of viral vector gene therapy for rare genetic diseases including the discovery, development and engineering of novel viral vectors for in vivo gene delivery as well as preclinical and clinical gene therapy product development. He has also made significant contributions to the development of viral vector manufacturing for gene therapy applications and the development of technology platforms for novel gene therapy approaches in humans. Dr. Gao has published nearly 300 research papers and serves as the Executive Editor-In-Chief of Human Gene Therapy, Senior Editor of the Gene and Cell Therapy book series and serves on the Editorial Boards of several other gene therapy and virology journals. In addition to previously serving as President of ASGCT, he is an elected fellow of the U.S. National Academy of Inventors, holding 174 patents and an additional 373 patent applications pending with over 10 licensed to pharmaceutical companies. Dr. Gao is co-founder of Voyager Therapeutics, Adrenas Therapeutics and Aspa Therapeutics.

About Sio Gene Therapies

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit http://www.siogtx.com.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "will," "expect," "believe," "estimate," and other similar expressions are intended to identify forward-looking statements. For example, all statements Sio makes regarding costs associated with its operating activities are forward-looking. All forward-looking statements are based on estimates and assumptions by Sios management that, although Sio believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Sio expected. Such risks and uncertainties include, among others, the impact of the Covid-19 pandemic on our operations, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the development of a suspension-based manufacturing process for Axo-Lenti-PD; the scaling up of manufacturing, the expectations for regulatory submissions and approvals; the continued development of our gene therapy product candidates and platforms; Sios scientific approach and general development progress; and the availability or commercial potential of Sios product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Sios most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2020, as updated by its subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Sio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media and Investors

Parag MeswaniSio Gene Therapies, Inc.Chief Commercial Officerinvestors@siogtx.com

Josephine Belluardo, Ph.D.LifeSci Communications(646) 751-4361jo@lifescicomms.cominfo@siogtx.com

Follow this link:
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor - BioSpace

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) onNovember 17, 2020issued a composition of matter patent, U.S. Patent No. 10,837,028,with claims directed to the AAV vector used in PR001, Prevails experimental gene therapy program for the treatment of Parkinsons disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). The base patent term extends until October 3, 2038, excluding patent term extensions or coverage in additional related patent filings.

We are excited to make important progress this year with PR001, which is being evaluated in the Phase 1/2 PROPEL trial for patients with Parkinsons disease with GBA1 mutations and in the Phase 1/2 PROVIDE trial for patients with Type 2 Gaucher disease, said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. We are advancing clinical development of PR001 to make a potentially transformative difference for these patients who currently have no approved treatment options.

The Company recently announced that patient dosing has continued in the Phase 1/2 PROPEL clinical trial of PR001 for PD-GBA patients, and it expects to provide the next biomarker and safety analysis on a subset of patients in the PROPEL trial by mid-2021. The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for nGD in 2021.

The U.S. Food and Drug Administration has granted Fast Track designations for PR001 for the treatment of PD-GBA and nGD. In addition, the FDA granted PR001 Rare Pediatric Diseasedesignation for the treatment of nGD, and Orphan Drugdesignation for the treatment of patients with Gaucher disease.

About Prevail TherapeuticsPrevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinsons disease with GBA1mutations (PD-GBA) and neuronopathic Gaucher disease (nGD); PR006 for patients with frontotemporal dementia withGRNmutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr.Asa Abeliovichin 2017, through a collaborative effort withThe Silverstein Foundationfor Parkinsons with GBA and OrbiMed, and is headquartered inNewYork, NY.

Forward-Looking Statements Related to PrevailStatements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning the potential for Prevails gene therapy candidates to make a transformative difference for patients with neurodegenerative diseases; the expected timing of reporting additional interim data on a subset of patients from the PROPEL trial; and the anticipated timing of enrollment of and the next update on data from the PROVIDE trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevails novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevails gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevails filings with the Securities and Exchange Commission (SEC), including the Risk Factors sections of the Companys most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:Lisa QuTen Bridge Communications LQu@tenbridgecommunications.com678-662-9166

Investor Contact:investors@prevailtherapeutics.com

Read the original post:
Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 - GlobeNewswire

Catalent has appointed Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. In this new role, Dr. Mahdavi will join a team of experts in Catalents Science and Technology Group that works with customers and external innovators in both small and large molecules, to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques. He reports to Julien Meissonnier, Catalents Chief Scientific Officer.

Dr. Mahdavi has more than 20 years of experience in developing and implementing growth strategies in the biopharmaceutical industries. Dr. Mahdavi joins Catalent after a 13-year career at Lonza, where he held the role of Vice President Strategic Innovation & Alliances, and various board-level positions at other innovative companies. Prior to joining Lonza, he was Chief Executive Officer of SAM Electron Technologies.

As a company, Catalent continues to invest in the rapidly evolving and growing areas of cell and gene therapies and next-generation biopharmaceuticals, which are redefining the landscape of treating diseases, commented Mr. Meissonnier. I am delighted to welcome Behzad to Catalent, as he brings significant experience in leveraging accelerated innovation with strategic external sourcing, to further strengthen our strategy of delivering the therapies of tomorrow to patients faster, and more efficiently.

View post:
Catalent Appoints Open Innovation, Biologics, Cell And Gene Therapy VP - Contract Pharma

For the first time, researchers at the Center for Cell-Based Therapy (CTC) in Ribeiro Preto, Brazil, have identified a non-hereditary mutation in blood cells from a patient with GATA2 deficiency.

GATA2 deficiency is a rare autosomal disease caused by inherited mutations in the gene that encodes GATA-binding protein 2 (GATA2), which regulates the expression of genes that play a role in developmental processes and cell renewal.

An article on the study is publishedin the journalBlood.

The non-hereditary mutation may have acted as a natural gene therapy which prevented the disease from damaging the process of blood cell renewal. This meant that the patient did not develop such typical clinical manifestations as bone marrow failure, hearing loss, and lymphedema.

The researchers say that the findings pave the way for the use of gene therapy and changes to the process of checking family medical history and medical records for families with the hereditary disorder.

Luiz Fernando Bazzo Catto, first author of the article, said: When a germline [inherited] mutation in GATA2 is detected, the patients family has to be investigated because there may be silent cases.

The discovery was made when two sons were receiving medical treatment at the blood centre of the hospital run by FMRP-USP, both of which, in post-mortem DNA sequencing, showed germline mutations and GATA2 deficiency diagnosis. The researchers used next generation sequencing to estimate the proportion of normal blood cells in the fathers bone marrow, preventing clinical manifestations of GATA2 deficiency, and of cells similar to his childrens showing that 93% of his leukocytes had the mutation that protects from the clinical manifestations of GATA2 deficiency.

Following the sequencing of the fathers T-lymphocytes, the researchers found that the mutation occurred early in their lives and in the development of hematopoietic stem cells, which have the potential to form blood.

They also measured the activity of the blood cells, to see if they could maintain the activity of inducing normal cell production for a long time, by measuring the telomeres of his peripheral blood leukocytes. Telomeres are repetitive sequences of non-coding DNA at the tip of chromosomes that protect them from damage. Each time cells divide, their telomeres become shorter. They eventually become so short that division is no longer possible, and the cells die or become senescent.

The telomeres analysed by the researchers were long, indicating that the cells can remain active for a long time.

The researchers hypothesised that the existence of the somatic mutation in the fathers blood cells, and its restoration of the blood cell renewal process, may have contributed to the non-manifestation of extra-haematological symptoms of GATA2 deficiency such as deafness, lymphedema, and thrombosis.

Professor Rodrigo Calado, a corresponding author of the article, said: A sort of natural gene therapy occurred in this patient. Its as if he embodied an experiment and a medium-term prospect of analogous gene therapy treatment in patients with GATA2 deficiency.

The findings help us understand better how stem cells can recover by repairing an initial genetic defect.

Recommended Related Articles

See the rest here:
Non-hereditary mutation acts as natural gene therapy for GATA2 deficiency - Health Europa

Vivet Therapeutics and Pfizer are one step closer to bringing a gene therapy for a rare liver disorder into the clinic.

The companies announced Wednesday morning that the FDA has accepted its IND application for a Phase I/II study in the treatment of Wilsons disease. The study, evaluating a program dubbed VTX-801, is expected to launch early next year.

VTX-801 is an rAAV-based gene therapy vector designed to deliver a protein called ATP7B in the hopes of restoring copper homeostasis, reversing liver pathology and reducing copper accumulation in the brain, as it was shown to do in mouse models.

The study will be open label and not be randomized. Researchers will give a one-time IV infusion of the gene therapy in up to 16 adult patients, with the goal of evaluating three different dosage levels. Ultimately, the companies set a primary endpoint for safety and tolerability after 52 weeks.

In March 2019, Pfizer acquired a minority stake in the company, and in September, the big pharma agreed to manufacture the VTX-801 vector for this Phase I/II study. Max Gelman

Florida-based biotech Generex has inked the biggest deal (it) could even imagine, bagging $50 million from a consortium of Chinese institutions that licensed its Ii-Key vaccine tech for infectious diseases and cancer.

Comprising hybrid peptides and a suppression, the platform has spawned a vaccine candidate against SARS-CoV-2 in addition to a pipeline of immuno-oncology therapies.

We are able to generate a detailed immune activation profile of our Ii-Key vaccine candidates by screening blood samples from COVID-19 recovered patients, explained Richard Purcell, EVP of R&D.

In addition to the upfront fee for the overall deal, the unnamed partners have handed over $5 million to license the Covid-19 vaccine candidate and promised a $20 million success fee if its approved in China. Separate contracts for the other indications are being finalized. Amber Tong

Excerpt from:
News briefing: Pfizer and Vivet get the OK to start gene therapy trial for rare liver disorder; Florida biotech inks $50M China deal - Endpoints News

Just a few months after withdrawing its IPO filing, 4D Molecular Therapeutics is seeking to go public once again.

The Emeryville, CA-based company submitted a new S-1 on Tuesday, detailing plans for a $75 million raise as it aims for the second time to hit the Nasdaq. 4DMT had previously sought a $100 million IPO back in September 2019, but withdrew the filing in July of this year after completing a $75 million Series C in June.

Should 4DMT complete the transition to a public company this time around, theyll join a crowded IPO party thats lasted nearly the entire year.

Nasdaq head of healthcare listings Jordan Saxe provided the most recent tally for biotech IPOs in late October, counting 72 companies going public at the time. Combined, those outlets have raised roughly $13.2 billion. The debuts have slowed since the summer, but Saxe pegged a fair estimate of 75 IPOs and just under $14 billion in proceeds to round out 2020.

Several factors have contributed to this years wave, Saxe previously told Endpoints News, as the Covid-19 pandemic has highlighted innovation and crossover investors have steadily increased biotech investments in the second half of the 2010s. The pandemic economy has also made biotech companies more appealing given that theyre less reliant on quarter-to-quarter sales numbers.

In the last four years, only 2018 comes close in terms of the sheer amount of biotechs shooting for Wall Street. That years tab totaled 56 IPOs, according to independent analyst Brad Loncar.

Within the new S-1, 4DMT didnt provide too much detail about how much money theyd spend on each of their programs. The company did list, however, that ongoing clinical trials for their leading programs 4D-310 and 4D-125 would be their top priority. Both of those candidates are currently in Phase I/II with data likely coming next year.

The main research driving the company has been building out a base of more than a billion vector capsid sequences, which CEO David Kirn said in June needed years to take place. 4DMT needed that time to run the sequences through non-human primates to see which shells were the least toxic and most likely to prevent antibody resistance.

By doing so, the biotech hopes this screening model can help find the capsids most suitable for the vector delivery of gene therapies.

4DMTs lead candidate, 4D-310, is intended to treat Fabry disease, with the goal of initially treating early onset versions before expanding into severe, late-onset patients. 4D-125, meanwhile, has the goal of treating an inherited vision loss disorder called XLRP. Roche has partnered with 4DMT to in-license the program before it begins a pivotal trial.

The biotech is also conducting a Phase I study in 4D-110, which is targeted at patients with choroideremia related to mutations in the CHM gene.

Read the rest here:
4DMT shoots for a $75M IPO, its second attempt to go public with its gene therapy vector programs - Endpoints News

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the new 100 mg/mL intravenous (IV) formulation of ULTOMIRIS (ravulizumab) for the treatment of two ultra-rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ULTOMIRIS is the first and only long-acting C5 inhibitor administered to patients every eight weeks or every four weeks for pediatric patients less than 20 kg. ULTOMIRIS 100 mg/mL is an advancement in the treatment experience for patients with aHUS and PNH by reducing average annual infusion times by approximately 60 percent compared to ULTOMIRIS 10 mg/mL, while delivering comparable safety and efficacy. With ULTOMIRIS 100 mg/mL, most patients will spend six hours or less a year receiving treatment.

ULTOMIRIS has already provided patients with greater flexibility and this new formulation is another step forward in reducing the overall treatment burden, said Professor Alexander Rth, Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany. With this new formulation, patients will experience comparable safety and efficacy to the original formulation while spending significantly less time per year receiving treatment, which has the potential to make a meaningful difference in their lives.

PNH is a blood disorder characterized by complement-mediated destruction of the red blood cells that can cause a wide range of debilitating symptoms and complications, including thrombosis, which can occur throughout the body, and result in organ damage and premature death.1 Atypical HUS can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots.2 Affecting both adults and children, aHUS patients can present in critical condition, often requiring supportive care, including dialysis, in an intensive care unit. The prognosis of both aHUS and PNH can be poor in many cases, so a timely and accurate diagnosisin addition to appropriate treatmentis critical to improving patient outcomes.

The European Commissions approval of ULTOMIRIS in this new formulation will provide a meaningful benefit to patients quality of life, said John Orloff, M.D., Executive Vice President and Head of Research & Development at Alexion. This new formulation demonstrates Alexions continued commitment to innovating for patients and their families. In addition, it lessens the overall burden on healthcare systems and practitioners with reduced infusion times, and on patients, who will only spend six hours or less a year receiving their treatment.

The European Commission approval is based on a comprehensive chemistry, manufacturing and control submission and a supplementary clinical data set showing that the safety, pharmacokinetics and immunogenicity following administration of ULTOMIRIS 10 mg/mL and ULTOMIRIS 100 mg/mL were comparable. Similarly, the data set showed no relevant changes in the efficacy measure of mean lactate dehydrogenase (LDH) levels across the two formulations. The new proposed formulation requires an infusion time of 0.4 to 1.3 hours (25 to 75 minutes) depending on body weight, reducing the infusion time by approximately 60 percent compared with the currently available 10 mg/mL IV formulation, which ranges from 1.3 to 3.3 hours (77 to 194 minutes) depending on body weight.

ULTOMIRIS 100 mg/mL was approved by the U.S. Food and Drug Administration (FDA) in October 2020, and a regulatory filing is under review in Japan.

Alexion continues to innovate with ULTOMIRIS, with the goal of improving the patient experience. We plan to submit regulatory filings in the U.S. and EU in the third quarter of 2021 for an ULTOMIRIS subcutaneous formulation and device combination for PNH and aHUS that can be self-administered at home, pending completion of the ongoing Phase 3 study and collection of 12-month safety data. In addition, the collective ULTOMIRIS clinical development programs present an opportunity to expand treatment for rare diseases across hematology, nephrology, neurology, and for the treatment of severe COVID-19, with seven Phase 3 programs that are ongoing or have planned clinical trial initiations in 2020.

About Paroxysmal Nocturnal Hemoglobinuria (PNH)PNH is a serious ultra-rare blood disorder with devastating consequences. It is characterized by the destruction of red blood cells, which is also referred to as hemolysis. PNH occurs when the complement systema part of the bodys immune systemover-responds, leading the body to attack its own red blood cells. PNH often goes unrecognized, with delays in diagnosis from one to more than five years.Patients with PNH may experience a range of symptoms, such as fatigue, difficulty swallowing, shortness of breath, abdominal pain, erectile dysfunction, dark-colored urine and anemia. The most devastating consequence of chronic hemolysis is the formation of blood clots, which can occur in blood vessels throughout the body, damage vital organs, and potentially lead to premature death.PNH can strike men and women of all races, backgrounds and ages without warning, with an average age of onset in the early 30s.

About Atypical Hemolytic Uremic Syndrome (aHUS)aHUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots. aHUS occurs when the complement systema part of the bodys immune systemover-responds, leading the body to attack its own healthy cells. aHUS can cause sudden organ failure or a slow loss of function over timepotentially resulting in the need for a transplant, and in some cases, death. aHUS affects both adults and children, and many patients present in critical condition, often requiring supportive care, including dialysis, in an intensive care unit. The prognosis of aHUS can be poor in many cases, so a timely and accurate diagnosisin addition to treatmentis critical to improving patient outcomes. Available tests can help distinguish aHUS from other hemolytic diseases with similar symptoms.

About ULTOMIRISULTOMIRIS (ravulizumab) is the first and only long-acting C5 complement inhibitor. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the bodys immune system. When activated in an uncontrolled manner, the complement cascade over-responds, leading the body to attack its own healthy cells. ULTOMIRIS is administered intravenously every eight weeks or, for pediatric patients less than 20 kg, every four weeks, following a loading dose. ULTOMIRIS is approved in the United States (U.S.), European Union (EU) and Japan as a treatment for adults with paroxysmal nocturnal hemoglobinuria (PNH). It is also approved in the U.S. and Japan for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and pediatric (one month of age and older) patients, as well as in the EU for the treatment of adults and children with a body weight of at least 10 kg with aHUS. In the U.S., ULTOMIRIS is available in two formulations with the same mechanism of action and consistent safety and efficacy. The ULTOMIRIS 100 mg/mL formulation reduces average annual infusion time for patients with aHUS and PNH by approximately 60 percent (to approximately 45 minutes for adults in the average weight cohort) compared to the ULTOMIRIS 10 mg/mL formulation. To learn more about the regulatory status of ULTOMIRIS in the countries that we serve, please visit http://www.alexion.com.

About AlexionAlexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This press release and further information about Alexion can be found at: http://www.alexion.com.

[ALXN-P]

Forward-Looking StatementThis press release contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Alexion, including statements related to: the safety, efficacy and benefits of the 100 mg/mL ULTOMIRIS formulation as a treatment for PNH and aHUS; that ULTOMIRIS 100 mg/mL formulation reduces infusion time as compared to the 10 mg/mL formulation of ULTOMIRIS by approximately 60% with comparable safety and efficacy; with ULTOMIRIS 100 mg/mL, most patients will spend six hours or less a year receiving treatment; this new formulation is another step forward in reducing the overall treatment burden; patients will experience comparable safety and efficacy to the original formulation while spending significantly less time per year receiving treatment; that shorter infusion times will make a meaningful difference in patient lives; that this new formulation demonstrates Alexions continued commitment to innovating for patients and their families; that 100 mg/mL ULTOMIRIS lessens the overall burden on healthcare systems and practitioners with reduced infusion times, and on patients, who will only spend six hours or less a year receiving their treatment; Alexion plans to submit regulatory filings in the U.S. and EU in the third quarter of 2021 for an ULTOMIRIS subcutaneous formulation and device combination for PNH and aHUS that can be self-administered at home; the collective ULTOMIRIS clinical development programs present an opportunity to expand treatment for rare diseases across hematology, nephrology, neurology, and for the treatment of severe COVID-19; and that Alexion has seven Phase 3 programs that are ongoing or have planned clinical trial initiations in 2020. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those expected by these forward looking statements, including for example: the anticipated safety profile and the benefits of the ULTOMIRIS 100 mg/ml formulation may not be realized (and the results of the clinical trials may not be indicative of future results); results of clinical trials may not be sufficient to satisfy regulatory authorities; results in clinical trials may not be indicative of results from later stage or larger clinical trials (or in broader patient populations); the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to discontinue sales of the product (or halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates); the severity of the impact of the COVID-19 pandemic on Alexions business, including on commercial and clinical development programs; unexpected delays in clinical trials; unexpected concerns regarding products and product candidates that may arise from additional data or analysis obtained during clinical trials or obtained once used by patients following product approval; future product improvements may not be realized due to expense or feasibility or other factors; delays (expected or unexpected) in the time it takes regulatory agencies to review and make determinations on applications for the marketing approval of our products; inability to timely submit (or failure to submit) future applications for regulatory approval for our products and product candidates; inability to timely initiate (or failure to initiate) and complete future clinical trials due to safety issues, IRB decisions, CMC-related issues, expense or unfavorable results from earlier trials (among other reasons); our dependence on sales from our principal product (SOLIRIS); future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by regulatory agencies regarding our products and product candidates; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete acquisitions or grow the product pipeline through acquisitions (including due to failure to obtain antitrust approvals); the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized or that tax liabilities exceed current expectations; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; adverse impacts on our supply chain, clinical trials, manufacturing operations, financial results, liquidity, hospitals, pharmacies and health care systems from natural disasters and global pandemics, including COVID-19; uncertainties surrounding legal proceedings, company investigations and government investigations; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing (as well as patients requiring a Factor Xa inhibitor reversal agent) are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisitions of Portola Pharmaceuticals, Achillion and other companies and co-development efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended September 30, 2020 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

References

Short ULTOMIRIS SmPC June 2020

ULTOMIRIS (ravulizumab) Prescribing Information

Please refer to the SmPC for further information before prescribing.

ULTOMIRIS 300 mg concentrate for solution for infusion

Qualitative and quantitative composition: One vial of 30 mL contains 30 0mg of ravulizumab, produced in Chinese hamster ovary (CHO) cell culture by recombinant DNA technology. After dilution, the final concentration of the solution to be infused is 5 mg/mL. Excipient(s) with known effect: Sodium (5 mmol per vial). Clear to translucent, slight whitish colour, pH 7.0 solution.

Therapeutic indication: Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. Treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-nave or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Posology and method of administration. Posology: The recommended dosing regimen consists of a loading dose followed by maintenance dosing, administered by intravenous infusion. The doses to be administered are based on the patients body weight. For adult patients ( 18 years of age), maintenance doses should be administered at a once every 8 week interval, starting 2 weeks after loading dose administration. Dosing schedule is allowed to occasionally vary by 7 days of the scheduled infusion day (except for the first maintenance dose of ravulizumab) but the subsequent dose should be administered according to the original schedule. For patients switching from eculizumab to ravulizumab, the loading dose of ravulizumab should be administered 2 weeks after the last eculizumab infusion, and then maintenance doses are administered once every 8 weeks, starting 2 weeks after loading dose administration. Ravulizumab has not been studied in patients with PNH who weigh less than 40 kg. There is no experience of concomitant PE/PI (plasmapheresis or plasma exchange, or fresh frozen plasma infusion) use with ravulizumab. Administration of PE/PI may reduce ravulizumab serum levels. In aHUS, ravulizumab treatment to resolve TMA manifestations should be for a minimum duration of 6 months, beyond which length of treatment needs to be considered for each patient individually. Patients who are at higher risk for TMA recurrence, as determined by the treating healthcare provider (or clinically indicated), may require chronic therapy. Special Populations: Paediatric patients with aHUS with body weight 40 kg are treated in accordance with the adult dosing recommendations. The weight-based doses and dosing intervals for paediatric patients 10 kg to 20 kg is once every 4 week interval, for paediatric patients 20 kg to 40 kg once every 8 weeks, starting 2 weeks after loading dose administration. Data to support safety and efficacy of ravulizumab for patients with body weight below 10 kg are limited. No recommendation on a posology can be made for patients below 10 kg body weight (please refer to the SmPC for currently available data). The safety and efficacy of ravulizumab in children with PNH aged 0 to < 18 years have not been established. No data are available. Method of administration: For intravenous infusion only. ULTOMIRIS must be diluted to a final concentration of 5 mg/mL. This medicinal product must be administered through a 0.2 m filter and should not be administered as an intravenous push or bolus injection. ULTOMIRIS must be diluted prior to administration by intravenous infusion over a minimal period of 1.7 to 2.4 hours depending of body weight (please refer to the SmPC).

Contraindications: Hypersensitivity to the active substance or to any of the excipients; in patients with unresolved Neisseria meningitidis infection at treatment initiation; in patients who are not currently vaccinated against Neisseria meningitidis unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination. Special warnings and precautions for use. Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Serious meningococcal infection: Due to its mechanism of action, the use of ravulizumab increases the patient's susceptibility to meningococcal infection/sepsis (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce this risk of infection, all patients must be vaccinated against meningococcal infections at least two weeks prior to initiating ravulizumab unless the risk of delaying ravulizumab therapy outweighs the risk of developing a meningococcal infection. Patients who initiate ravulizumab treatment less than 2 weeks after receiving a meningococcal vaccine, must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W135 and B where available, are recommended in preventing the commonly pathogenic meningococcal serogroups. Patients must be vaccinated or revaccinated according to current national guidelines for vaccination use. If the patient is being switched from eculizumab treatment, physicians should verify that meningococcal vaccination is current according to national guidelines for vaccination use. Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious meningococcal infections/sepsis have been reported in patients treated with ravulizumab. Cases of serious or fatal meningococcal infections/sepsis have been reported in patients treated with other terminal complement inhibitors. All patients should be monitored for early signs of meningococcal infection and sepsis, evaluated immediately if infection is suspected, and treated with appropriate antibiotics. Patients should be informed of these signs and symptoms and steps should be taken to seek medical care immediately. Physicians should provide patients with a patient information brochure and a patient safety card. Immunization: Prior to initiating ravulizumab therapy, it is recommended that PNH and aHUS patients initiate immunizations according to current immunization guidelines. Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH and aHUS, may experience increased signs and symptoms of their underlying disease, such as haemolysis. Therefore, patients should be closely monitored for disease symptoms after recommended vaccination. Patients below the age of 18 years old must be vaccinated against Haemophilus influenzae and pneumococcal infections, and strictly need to adhere to the national vaccination recommendations for each age group. Other systemic infections: Ravulizumab therapy should be administered with caution to patients with active systemic infections. Ravulizumab blocks terminal complement activation; therefore, patients may have increased susceptibility to infections caused by Neisseria species and encapsulated bacteria. Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported. Patients should be provided with information from the Package Leaflet to increase their awareness of potential serious infections and their signs and symptoms. Physicians should advise patients about gonorrhea prevention. Infusion reactions: Administration of ravulizumab may result in infusion reactions. In clinical trials, with PNH and aHUS [(4 out of 296 in patients with PNH) and (4 of 89 patients with aHUS)] patients experienced infusion reactions which were mild in severity and transient [e.g., lower back pain, drop in blood pressure, elevation in blood pressure, limb discomfort, drug hypersensitivity (allergic reaction), and dysgeusia(bad taste)]. In case of infusion reaction, infusion of ravulizumab should be interrupted and appropriate supportive measures should be instituted if signs of cardiovascular instability or respiratory compromise occur.

Treatment discontinuation for PNH: If patients with PNH discontinue treatment with ravulizumab, they should be closely monitored for signs and symptoms of serious intravascular haemolysis, identified by elevated LDH (lactate dehydrogenase) levels along with sudden decrease in PNH clone size or haemoglobin, or re-appearance of symptoms such as fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction. Any patient who discontinues ravulizumab should be monitored for at least 16 weeks to detect haemolysis and other reactions. If signs and symptoms of haemolysis occur after discontinuation, including elevated LDH, consider restarting treatment with ravulizumab. Treatment discontinuation for aHUS: There are no specific data on ravulizumab discontinuation. In a long-term prospective observational study, discontinuation of complement C5 inhibitor treatment (eculizumab) resulted in a 13.5-fold higher rate of TMA recurrence and showed a trend toward reduced renal function compared to patients who continued treatment. If patients must discontinue treatment with ravulizumab, they should be monitored closely for signs and symptoms of TMA on an on-going basis. However, monitoring may be insufficient to predict or prevent severe TMA complications. TMA complications post-discontinuation can be identified if any of the following is observed: (i) At least two of the following laboratory results observed concurrently: a decrease in platelet count of 25% or more as compared to either baseline or to peak platelet count during ravulizumab treatment; an increase in serum creatinine of 25% or more as compared to baseline or to nadir during ravulizumab treatment; or, an increase in serum LDH of 25% or more as compared to baseline or to nadir during ravulizumab treatment (results should be confirmed by a second measurement), or (ii) any one of the following symptoms of TMA: a change in mental status or seizures or other extra-renal TMA manifestations including cardiovascular abnormalities, pericarditis, gastrointestinal symptoms/diarrhoea; or thrombosis. If TMA complications occur after ravulizumab discontinuation, consider reinitiation of ravulizumab treatment beginning with the loading dose and maintenance dose. This medicinal product when diluted with sodium chloride 9 mg/mL (0.9 %) solution for injection contains 2.65 g sodium per 720 mL at the maximal dose, equivalent to 133 % of the WHO recommended maximum daily intake of 2 g sodium for an adult. Interaction with other medicinal products and other forms of interaction: No interaction studies have been performed. Chronic intravenous human immunoglobulin (IVIg) treatment may interfere with the endosomal neonatal Fc receptor (FcRn) recycling mechanism of monoclonal antibodies such as ravulizumab and thereby decrease serum ravulizumab concentrations. Fertility, pregnancy and lactation. Women of childbearing potential: Women of childbearing potential should use effective contraception methods during treatment and up to 8 months after treatment. Pregnancy: There are no clinical data from the use of ravulizumab in pregnant women. Nonclinical reproductive toxicology studies were not conducted with ravulizumab. Reproductive toxicology studies were conducted in mice using the murine surrogate molecule BB5.1, which assessed effect of C5 blockade on the reproductive system. No specific test-article related reproductive toxicities were identified in these studies. Human IgG are known to cross the human placental barrier, and thus ravulizumab may potentially cause terminal complement inhibition in the foetal circulation. Animal studies are insufficient with respect to reproductive toxicity. In pregnant women the use of ravulizumab may be considered following an assessment of the risks and benefits. Breast-feeding: It is unknown whether ravulizumab is excreted into human milk. Nonclinical reproductive toxicology studies conducted in mice with the murine surrogate molecule BB5.1 identified no adverse effect to pups resulting from consuming milk from treated dams. A risk to infants cannot be excluded. Since many medicinal products and immunoglobulins are secreted into human milk, and because of the potential for serious adverse reactions in nursing infants, breast-feeding should be discontinued during treatment with ravulizumab and up to 8 months after treatment. Fertility: No specific non-clinical study on fertility has been conducted with ravulizumab. Nonclinical reproductive toxicology studies conducted in mice with a murine surrogate molecule (BB5.1) identified no adverse effect on fertility of the treated females or males.

Undesirable effects. Summary of the safety profile: The most common adverse drug reactions (very common frequency) are diarrhea, nausea, vomiting, nasopharyngitis and headache. The most serious adverse reactions in patients in clinical trials are meningococcal infection and meningococcal sepsis. Tabulated list of adverse reactions: Very common adverse reactions observed from PNH and aHUS clinical trials (1/10): Upper respiratory tract infection, Nasopharyngitis, Headache, Diarrhoea, Nausea, Pyrexia, Fatigue. Common adverse reactions (1/100 to <1/10): Dizziness, Abdominal pain, Vomiting, Dyspepsia, Rash, Pruritus, Arthralgia, Back pain, Myalgia, Muscle spasms, Influenza like illness, Asthenia. Uncommon adverse reactions (1/1,000 to <1/100): Meningococcal infection, Chills. In paediatric patients with evidence of aHUS (aged 10 months to less than 18 years) included in the clinical study, the safety profile of ravulizumab appeared similar to that observed in adult patients with evidence of aHUS. The safety profiles in the different paediatric subsets of age appear similar. The safety data for patient below 2 years of age is limited to four patients. The most common adverse reaction reported in paediatric patients was pyrexia. The safety of ravulizumab in children with PNH aged 0 to < 18 years have not been established. No data are available.

Storage: 2C 8C. Marketing Authorization Holder: Alexion Europe SAS, 1-15, 103-105 rue Anatole France, 92300 Levallois-Perret, FRANCE.

Marketing Authorisation Number: EU/1/19/1371/001. Date of First Authorisation: {02 July 2019}. Date of revision: {25 June 2020}. Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/.

Excerpt from:
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS (ravulizumab) with Significantly Reduced Infusion...

The UN is calling for authoritative scientific information and research to be made freely available, to accelerate research into an effective vaccine against the COVID-19 virus, help counter misinformation, and unlock the full potential of science.

Arguing that no-one is safe until everyone is safe, the World Health Organization (WHO) has, for several months, been urging countries and scientists to collaborate, in a bid to bring the pandemic under control. This has involved the creation, alongside governments, scientists, foundations, the private sector and other partners, of a groundbreaking platform to accelerate the development of tests, treatments and vaccines.

In October, the head of the agency, Tedros Ghebreyesus Adhanom, alongside human rights chief Michelle Bachelet, and Audrey Azoulay, Director-General of science, culture and education agency UNESCO, issued a call for Open Science, describing it as a fundamental matter of human rights, and arguing for cutting-edge technologies and discoveries to be available for those who need them most.

But what exactly does Open Science mean, and why does the UN insist on making it more widespread?

Open Science has been described as a growing movement aimed at making the scientific process more transparent and inclusive by making scientific knowledge, methods, data and evidence freely available and accessible for everyone.

The Open Science movement has emerged from the scientific community and has rapidly spread across nations. Investors, entrepreneurs, policy makers and citizens are joining this call.

However, the agency also warns that, in the fragmented scientific and policy environment, a global understanding of the meaning, opportunities and challenges of Open Science is still missing.

Open Science facilitates scientific collaboration and the sharing of information for the benefit of science and society, creating more and better scientific knowledge, and spreading it to the wider population.

UNESCO has described Open Science as a true game changer: by making information widely available, more people can benefit from scientific and technological innovation.

Because, in a world that is more inter-connected than ever before, many of todays challenges do not respect political or geographic borders, and strong international scientific collaboration is essential to overcome the problems. The COVID-19 pandemic is a prime example.

We also have the tools to make it happen: with digitalization becoming ever more widespread, it is far easier than ever before to share scientific knowledge and data, which are needed to enable decisions that can lead to overcoming global challenges to be based on reliable evidence.

In this global health emergency, thanks to international collaboration, scientists have improved their understanding of the coronavirus with unprecedented speed and openness, embracing the principles of Open Science. Journals, universities, private labs, and data repositories have joined the movement, allowing open access to data and information: some 115,000 publications have released information related to the virus and the pandemic, and more than 80 per cent of them can be viewed, for free, by the general public.

Early in the pandemic, for example, Chinese scientists readily shared the genome of the virus, jumpstarting all following research into the virus, and the diagnostic testing, treatments, and vaccines that have since been developed.

Finally, the crisis has underlined the urgent need to bring science closer to decision making and to society as a whole. Fighting misinformation and promoting evidence-based decision-making, supported by well-informed citizens, has proven to be of vital importance in the fight against COVID 19.

To ensure that Open Science truly meets its potential, and benefits both developed and developing countries, UNESCO is taking the lead in building a global consensus on values and principles for Open Science that are relevant for every scientists and every person independently of their place of origin, gender, age or economic and social background.

The future UNESCO Recommendation on Open Science is expected to be the international instrument to set the right and just standards for Open Science globally, which fulfil the human right to science and leave no one behind.

In a statement released on World Science Day for Peace and Development, celebrated on 10 November, Ms. Azoulay said that widening the scope of Open Science will help science to unlock its full potential, making it more effective and diverse by enabling anyone to contribute, but also to bring its objectives in line with the needs of society, by developing scientific literacy in an informed citizenry who take responsibility and are involved in collective decision-making.

Related

Read the original:
Cybersecurity depends on the user - Modern Diplomacy

One year ago, a mysterious illness emerged in Wuhan, China, marking the start of the coronavirus pandemic that has now killed more than 1.25 million people around the world and infected tens of millions more.

In March, the South China Morning Post published an article based on Chinese government data that showed the first known case of COVID-19 can be traced back to November 17, 2019possibly a 55-year-old individual from Hubei province, although "patient zero" has yet to be confirmed.

Chinese authorities did not officially identify the first case of the new disease until December 8, 2019.

Over the weeks that followed, medical staff in Wuhan treated dozens of patients suffering from pneumonia of unknown cause. The patients were treated for a range of unexplained symptoms including high fever, coughing and respiratory problems.

Among these individuals were an elderly couple who sought treatment at Hubei Provincial Hospital of Integrated Chinese and Western Medicine on December 26. A doctor at the hospital who attended to the couple, Zhang Jixian, later told Chinese state-run news agency Xinhua in April that the illness "looked like flu or common pneumonia."

But CT scan images revealed lung abnormalities that were not characteristic of either of these diseases.

Zhang had worked as a medical expert during the SARS outbreak that originated in China in 2003, which went on to kill more than 800 people around the world. Given her experience with this epidemiccaused by a pathogen in the coronavirus familyshe was attuned to the possibility that the elderly couple's illnesses could represent a new infectious disease.

Once the doctor had seen the couple's CT scans, she requested that their son be examined as well.

"At first their son refused to be examined. He showed no symptoms or discomfort, and believed we were trying to cheat money out of him," Zhang told state news agency Xinhua at the time.

Eventually, the son agreed to be examined, with his CT scans showing that he had the same lung abnormalities that were detected in his parents. "It is unlikely that all three members of a family caught the same disease at the same time unless it is an infectious disease," Zhang said.

On December 27, another patient arrived at the hospital suffering from a fever and cough who also turned out to have the same lung abnormalities as the three family members. Blood tests of this fourth patient and the family revealed that they were suffering from viral infections, although the exact cause of their symptoms was unclear, with influenza tests producing a negative result.

Zhang subsequently submitted a report to officials at the hospital reporting the discovery of a new "viral disease." At this point, it was still not clear whether or not the illness could be transmitted between people, but the doctor speculated it was "probably infectious."

Becoming increasingly concerned, Zhang placed the four patients in a provisional quarantine area in the hospital and ordered medical staff to wear personal protective equipment.

On December 29, three more patients arrived presenting with similar lung abnormalities, prompting the hospital to launch an internal investigation headed by a panel of experts, Chinese newspaper the Workers' Daily reported in February.

All of these patients were found to have been exposed to the Huanan Seafood Wholesale Market in Wuhanas did the fourth patient to arrive at Hubei Provincial Hospital with the mystery illness.

Hubei Provincial Hospital's internal investigation found that the unknown pneumonia cases were unusual and warranted further investigation, with medical staff reporting the situation to local health authorities on December 29.

This prompted a field investigation by the Wuhan Center for Disease Control and Prevention (CDC.) The investigation was aimed at uncovering more patients with pneumonia with potential links to the market.

On the same day, six of the seven patients with the new disease at Hubei Provincial were transferred to another medical centerthe Wuhan Jinyintan Hospitalwhich specializes in the treatment of infectious diseases.

The Wuhan CDC search turned up several additional cases and on December 30, health authorities from Hubei province reported the pneumonia cluster to the Chinese CDC. At this point, the Wuhan Municipal Health Commission sent out an alert, informing its affiliated institutions about how to respond to a possible outbreak of infectious pneumonia.

On the last day of 2019, the commission released the first public messaging regarding the pandemic, briefing Wuhan residents about a viral pneumonia outbreak. It reported a total of 27 confirmed cases, seven of which were in critical condition. The early evidence of the outbreak had also been reported on ProMEDone of the largest publicly available emerging disease reporting systems in the world.

While there was still no evidence of human-to-human transmission and the cause of the pneumonia was yet to be determined, Wuhan authorities advised people to wear face masks and avoid crowded areas.

The public health announcement was reported by local and national media in China, and was later picked up by a handful of international news outlets. Meanwhile, rumors were circulating on Chinese social media that the outbreak could be linked to the SARS virus.

"The cause of the disease is not clear," the state-run People's Daily newspaper said in a post on Chinese social media site Weibo. "We cannot confirm it is what's being spread online, that it is SARS virus. Other severe pneumonia is more likely."

China sent experts to Wuhan to conduct an investigation, take samples from the patients who were suffering from the new disease and support the control effort. Authorities had so far isolated all the patients and their close contacts were also being supervised.

By January 2, 41 patients had been admitted to hospital with the new disease, all of whom were relocated to the Jinyintan Hospital. Retrospective research conducted later in 2020 would find that the number of people infected by this point was significantly higher than this figure suggests.

According to the Chinese CDC, initial laboratory tests from patients suffering from the viral pneumonia were negative for 26 common respiratory pathogens. It was not until January 7 that Chinese scientists confirmed that a novel coronavirus, dubbed 2019-nCoV, was the cause of the mysterious pneumonia outbreak.

On January 24, a group of Chinese scientists published a report in The Lancet examining the 41 cases that had been admitted to hospital by January 2.

The paperthe first peer-reviewed, publicly available scientific study on the outbreakfound that 27 of these patients had been exposed to the Huanan seafood market, which had been shut down by Chinese authorities on January 1.

Thirteen of these patients were admitted to an ICU and six died, indicating a high mortality rate at the time. The study also found that the symptom onset date of the first patient identified was December 1, 2019.

The researchers admitted that there were still "major gaps" in their knowledge of the virusincluding where it originated.

Frederick Hayden, an infectious disease specialist and emeritus professor at the University of Virginia, who co-authored a Lancet editorial accompanying the Chinese study, told Newsweek that he first heard about the new illness when he spotted the ProMED Posting on December 30, 2019.

Read more

He quickly sent off emails to colleagues in Chinaincluding one of his previous collaborators, Bin Cao, at the China-Japan Friendship Hospital in Beijingto try and get more information.

"Obviously, I was concerned. I didn't know if it was possibly another SARS event, or a novel virus. In the very beginning, there were statements that it wasn't being transmitted from person to person. Of course, that was subsequently proven to be completely inaccurate. Based on discussions with Cao Bin early in January, it was clear that there was human transmissibility and that it could cause very severe disease. They were taking care of critically ill patients at the time."

Shangxin Yang, a microbiologist from UCLA Health, who has colleagues, family and friends near the coronavirus' epicenter in Wuhan, told Newsweek he had started hearing rumors in late December on Chinese social media that SARS had reappeared in the country. A Beijing-based health care company claimed it had detected the SARS virus in the analysis of a sample taken from a Wuhan patient who was actually infected with the novel coronavirus.

The detection of SARS, which was shared on social media by doctors, later turned out to be incorrect, with the company mistaking the novel coronavirus for SARS due to its very close genetic similarity.

"Obviously, it was very questionable at the timea lot of people were sceptical because SARS had disappeared for more than 10 years, since 2003," Yang said. "A reappearance of SARS would definitely be something shocking."

Yang didn't take the rumors of a new SARS outbreak very seriously until the end of the year, when he saw an image posted on Chinese social media showing a notice from Wuhan authorities in a local hospital alerting medical staff of the emerging pneumonia outbreak.

"I saw that and thought, 'that looks really real,' and I remember jumping out of bed. On one hand, you have a company who's using genetic sequencing to report this as SARS and on the other hand, you have authorities putting out this notice to all hospitals in Wuhan asking them to report any cases like that directly to local public health officials.

"It's then I realized it was a true outbreak. Whether it was a reemergence of SARS or a novel virus, at that time, I wasn't entirely sure, but I realized it's for real."

The graphic below, provided by Statista, shows the countries worst hit by the pandemic.

Over the course of January, international media took an increasing interest in the growing coronavirus outbreak as the virus spread around the world.

On January 12, China publicly shared the genetic sequence of the novel coronavirus. And just a day later, officials in Thailand confirmed a case of COVID-19the first outside China itself.

By January 20, the virus had spread all around China and to a handful of other countries including Japan, Thailand, South Korea and the United States, as governments scrambled to respond to the outbreak.

Chinese authorities locked down Wuhana city of 11 million peopleon January 23 as panic and confusion spread. COVID-19 cases were reported in Singapore and Vietnam for the first time, with the total confirmed global figure soaring past 500. At least 17 people had died from the new disease at this point.

The world watched on as China began building an emergency hospital in Wuhanwhich was completed in just 10 dayswhile images emerged of officials in personal protective equipment checked the temperatures of residents in Chinese cities.

By January 28, a delegation from the World Health Organization led by its Director-General Tedros Adhanom Ghebreyesus arrived in China to meet with the country's leadership and learn about the response of the authorities, as well as provide assistance.

Just two days later, with thousands of new cases confirmed in China, the WHO declared a "public health emergency of international concern" as the U.S. government warned Americans not to travel to China, and urged those in the country leave. Later in the year, on March 11with the virus now confirmed on every continent except Antarcticathe WHO declared that the COVID-19 outbreak was now a pandemic.

Long before the COVID-19 outbreak started, experts had been warning of the risks of a deadly global pandemic. In September 2019, shortly before the novel coronavirus emerged, a team of international scientists said in a report that efforts to prepare for such an event were "grossly insufficient." A year on, and lessons have been learned the hard way, with the future trajectory of the pandemic still far from certain.

Read the original here:
It's Been Exactly One Year Since the First Case of COVID Was Found in China - Newsweek

Organ and stem cell transplants are proven and frequently used methods in everyday modern clinical practice. However, even when performed regularly in specialized centers, some patients still experience a number of serious complications afterwards. Among other things, infections with fungi and viruses can jeopardize therapeutic success. For example, coinfection with cytomegalovirus, which belongs to the family of Herpes viruses, and the fungus Aspergillus fumigatus can be critical. This combination of pathogens poses a serious medical threat in organ and stem cell transplantation.

When viruses and fungi join forces

A team of scientists from several German research institutions and clinics has now developed a new method to examine these two pathogens, their interaction with each other and with the human cells infected by them. The central result: coinfection with the two pathogens is more "than the sum of its parts". Viruses and fungi interact synergistically in the human organism, where they trigger certain genes that only become active when infected with both pathogens simultaneously.

The study involved scientists from the Julius Maximilian University of Wrzburg (JMU), the Wrzburg University Hospital (UKW), the Leibniz Institute for Natural Product Research and Infection Biology in Jena and the Helmholtz Institute for RNA-based Infection Research (HIRI) in Wrzburg, a site of the Braunschweig Helmholtz Centre for Infection Research (HZI). The results have now been published in the journal Cell Reports.

New insights thanks to a novel technology

"For our study, we have developed a method called Triple RNA-seq," explains Alexander Westermann. He is junior professor at the Chair of Molecular Infection Biology I at JMU, as well as group leader at the HIRI. Together with Jrgen Lffler from UKW and Sascha Schuble he is one of the senior authors of the study. The scientists have advanced an established method that has been an integral part of infection research for years: dual RNA-seq.

The term "RNA-seq" is short for RNA-sequencing: This technique enables the simultaneous and precise determination of the activities of thousands of genes at the RNA level in a high-throughput process, thus enabling the identification and better understanding of the changes occurring in the course of diseases. The development of dual RNA sequencing has made it possible to document not only the gene activity of a pathogen, but also the reaction of the host cell affected by it. This has enabled scientists to trace complex causal chains over the course of an infection.

Research on immune cells

Now, Triple RNA sequencing dissects the gene expression of three players and their interplay in infection processes. "Up to now, science has in many cases not known why an infection with a certain pathogen can make the affected person more susceptible to an infection with a second pathogen," explains Jrgen Lffler, molecular biologist at the Medical Clinic II of the UKW. In such cases, dual RNA-seq was insufficient to provide the desired answers.

In their study, the researchers used the triple RNA-seq method they developed to investigate what happens when certain cells of the immune system (known as monocyte-derived dendritic cells) are infected with both Aspergillus fumigatus and the human cytomegalovirus.

They were able to prove that the two pathogens influence each other, whilst also simultaneously affecting the immune cell in a different way than one pathogen alone otherwise would. For example, the cytomegalovirus weakened the fungal-mediated activation of pro-inflammatory signals, while Aspergillus affects viral clearance - the time it takes for the virus to become undetectable in tests.

Hope for a biomarker

At the same time, the team has identified specific genes in immune cells whose expression profiles differ significantly during an infection with both pathogens, compared to a single infection. These genes could thus serve as biomarkers for the timely identification of a co-infection after transplantation.

The scientists now hope that the triple RNA-seq technology will also help to better understand other cases of common infections, such as viruses and bacteria, and to prevent their potentially serious consequences. "Promising models for understanding how an infection makes the host more susceptible to another pathogen include certain strains of Salmonella and the human immunodeficiency virus (HIV), streptococci and influenza virus, or Chlamydia and human herpes virus," says Westermann. As a next step, Westermann plans to use the triple RNA-seq technique to investigate infections in which two different types of bacteria jointly influence the course of the disease.

View original post here:
Coinfection: more than the sum of its parts - Science Codex

Pune, New York, USA, November 18 2020 (Wiredrelease) Research Dive :Big Market Research Add New Global Stem Cell Source Market by Manufacturers, Countries, Type and Application, forecast to 2026 to its research database presenting an informative study covering the market with detailed analysis. The Stem Cell Source market research report is a professional and in-depth study on the current state of global Industry.

This report provides in depth study of Stem Cell Source Market using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Stem Cell Source Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This market report offers a comprehensive analysis of the global Stem Cell Source market. This report focused on Stem Cell Source market past and present growth globally. Global research on Global Stem Cell Source Industry presents a market overview, product details, classification, market concentration, and maturity study. The market value and growth rate from 2020-2026 along with industry size estimates are explained.

Key players in the global Stem Cell Source market covered are: BD Bioscience, Beckman Coulter, Ge Healthcare, Merck Millipore, Miltenyi Biotec, Pluriselect Life Science, Sigma-Aldrich Corporation, Stemcell Technologies, Terumo BCT, Thermo Fisher Scientific Company

Request a sample of this premium research @ https://www.bigmarketresearch.com/request-sample/3903826

The Global Stem Cell Source Market has been segmented on the basis of technology, product type, application, distribution channel, end-user, and industry vertical, along with the geography, delivering valuable insights.

Stem Cell Source Breakdown Data by Type

Reagent Instrument Others

Stem Cell Source Breakdown Data by Application

1. Hospital2. Biotechnology Research Center3. Others

Regional and Country-level Analysis

1) North America- (United States, Canada)2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)3) Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)4) Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)5) Latin America- (Brazil, Mexico, Argentina, Colombia, Chile, Peru).

The analysis objectives of the report are:

To know the Global Stem Cell Source Market size by pinpointing its sub-segments. To study the important players and analyses their growth plans. To analyses the amount and value of the Global Stem Cell Source Market, depending on key regions To analyses the Global Stem Cell Source Market concerning growth trends, prospects and also their participation in the entire sector. To examine the Global Stem Cell Source Market size (volume & value) from the company, essential regions/countries, products and application, background information. Primary worldwide Global Stem Cell Source Market manufacturing companies, to specify, clarify and analyses the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for future. To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market.

With tables and figures helping analyses worldwide Global Stem Cell Source market growth factors, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a discount on standard prices of this premium research @ https://www.bigmarketresearch.com/request-for-discount/3903826

Table of Content:

Chapter 1 Study Coverage

Chapter 2 Executive Summary

Chapter 3 Global Stem Cell Source Competitor Landscape by Players

Chapter 4 Breakdown Data by Type (2015-2026)

Chapter 5 Breakdown Data by Application (2015-2026)

Chapter 6 North America

Chapter 7 Europe

Chapter 8 Asia Pacific

Chapter 9 Latin America

Chapter 10 Middle East and Africa

Chapter 11 Company Profiles

Chapter 12 Future Forecast by Regions (Countries) (2021-2026)

Chapter 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

Chapter 14 Value Chain and Sales Channels Analysis

Chapter 15 Research Findings and Conclusion

Chapter 16 Appendix

Flat 10% Discount on this Research Report [Use Code ORG127NN] @ https://www.bigmarketresearch.com/checkout/sales/22578

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:Mr. Abhishek PaliwalBig Market Research5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect: +1-971-202-1575Toll Free: +1-800-910-6452E-mail: help@bigmarketresearch.com

This content has been published by Research Dive company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Read more:
Stem Cell Source Market Technology Advancements and Business Outlook 2020-2026 - PharmiWeb.com

Stem Cell Assay Market research report is the new statistical data source added by A2Z Market Research.

Stem Cell Assay Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Stem Cell Assay Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=349580

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Bio-Techne Corporation, Promega Corporation, Merck KGaA, STEMCELL Technologies, GE Healthcare, Thermo Fisher Scientific, Cellular Dynamics International, Bio-Rad Laboratories, Hemogenix, Cell Biolabs

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Stem Cell Assay market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Stem Cell Assay markets trajectory between forecast periods.

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=349580

Global Stem Cell Assay Market Segmentation:

Market Segmentation by Type:

Viability/CytotoxicityIsolation & PurificationCell IdentificationProliferationDifferentiationFunctionApoptosis

Market Segmentation by Application:

Regenerative Medicine & Therapy DevelopmentDrug Discovery and DevelopmentClinical Research

Regions Covered in the Global Stem Cell Assay Market Report 2020:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The report provides insights on the following pointers:

Table of Contents

Global Stem Cell Assay Market Research Report 2020 2026

Chapter 1 Stem Cell Assay Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Stem Cell Assay Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=349580

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Read more here:
Comprehensive Report on Stem Cell Assay Market 2020 | Size, Growth, Demand, Opportunities & Forecast To 2026 | Bio-Techne Corporation, Promega...

Cell Therapy Market report examines Product Specification, Major Segments in Focus, Geographic Focus, Production Capacity, Production, Sales Performance of key players in market which gives you deep understanding of competitive scenario of Cell Therapy market. Cell Therapy industry research report enables reader to dive into consumers mind.

Cell Therapy market competition by top manufacturers, with production, price, and revenue (value) and market share for each manufacturer; the top players including:

JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost and many more.

Place an Enquiry to Our Industry Expert at @ https://www.adroitmarketresearch.com/contacts/request-sample/611

Goal Audience of Cell Therapy Market 2019 Forecast to 2026 Market:

Raw material suppliers->>Distributors/traders/wholesalers/suppliers->>Regulatory bodies, including government agencies and NGO->>Commercial research & development (R&D) institutions->>Importers and exporters->>Government organizations, research organizations, and consulting firms->>Trade associations and Cell Therapy industry bodies->>End-use industries

Cell Therapy Market 2019 forecast to 2026 Market Segment by Regions, regional analysis covers

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Enquiry for Discount Visit @ https://www.adroitmarketresearch.com/industry-reports/cell-therapy-market

Based on Product Type, Cell Therapy market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:

By Use & Type Outlook, (Clinical-use,By Cell Therapy Type,,Non-stem Cell Therapies,Stem Cell Therapies,BM, Blood, & Umbilical Cord-derived Stem Cells,Adipose derived cells,Others), By Therapeutic Area, (Malignancies,Muscoskeletal Disorders,Autoimmune Disorders,Dermatology,Others,Research-use), By Therapy Type, (Allogenic Therapies,Autologous Therapies)

Some of the important topics in Cell Therapy Market Research Report:

1. Cell Therapy Market Manufacturing Cost Analysis: Price Trend of Key Raw Materials, Key Raw Materials, Cell Therapy Market Concentration Rate of Raw Materials, Key Suppliers of Raw Materials, Proportion of Manufacturing Cost Structure, Raw Materials, Labor Cost, Manufacturing Expenses, Manufacturing Process Analysis of Cell Therapy market.

2. Industrial Chain, Sourcing Strategy and Downstream Buyers: Cell Therapy Industrial Chain Analysis, Upstream Raw Materials Sourcing, Raw Materials Sources of Cell Therapy market Major Manufacturers in 2019, Downstream Buyers.

3. Marketing Strategy Analysis, Distributors/Traders: Marketing Channel, Direct Marketing, Indirect Marketing, Marketing Channel Development Trend, Cell Therapy Market Positioning, Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List.

4. Cell Therapy Market Effect Factors Analysis: Technology Progress/Risk, Substitutes Threat, Technology Progress in Related Industry, Consumer Needs/Customer Preference Change, Economic/Political Environmental Change.

Questions answered in the global Cell Therapy market report:

1. What are the market strategies applicable, market insight, and Cell Therapy product type analysis?

2. What are driving factors influencing the growth of the global Cell Therapy market, analysis by region and application?

3. What are the market dynamics, that involves the scope of the product and price breakdown of Cell Therapy key manufacturers?

4. Who are the major challenges, opportunities and risk factors for Cell Therapy market, including the upstream and downstream towards raw material and buyers?

5. Who are the key market players, Cell Therapy business outline by application, product type, market share and gross profit?

6. What are major threats tackled by the sellers in the global Cell Therapy market?

The Cell Therapy current and past data related to market signifies the existing market valuation and the future prospects. Moreover, data collected here are through primary and secondary research, that includes interviews with major Cell Therapy industries including the values of top manufacturers, their suppliers, and various application, as well company report, latest trends, and reviews. Also, through different research findings, Cell Therapy distribution channels, traders, results, and Appendix.

For More Information Kindly Contact: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/611

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

See the original post:
Cell Therapy Market 2020-2025 Business Strategies JCR Pharmaceuticals Co., Ltd., Kolon TissueGene, Inc.; and Medipost - The Think Curiouser

Final Report will add the analysis of the impact of COVID-19 on this industry.

November 2020:

A new report by CMI takes a deep dive into the Stem Cell Assay after conducting meticulous research, assessing each microscopic aspect of the market. The researches have connected the dots with minuscule details that shape into an intricate, immaculate yet elucidate study. The report presents a thoroughly scrutinized study of the Stem Cell Assay Market, leaving no stone unturned in offering market players a valuable and constructive tool that navigates them in the profitable path with the right set of objectives.

This is the most recent report that includes the effects of COVID-19 on the functioning of the market. It is well known that some changes, for the worse, were managed by the pandemic in all industries. The current scenario of the business sector and the impact of the pandemic on the industrys past and future are addressed in this report.

Get a sample pages of this [emailprotected]: https://www.coherentmarketinsights.com/insight/request-sample/1632

The researchers have studied the factors that are expected to drive the growth of the Stem Cell Assay by creating revenue opportunities, directly and indirectly. Similarly, the emerging trends, both long-term and short-term, present factors that are likely to impact the markets growth and project the direction the whole market is moving. Economical, technological, or any other trend that could bestow opportunities, have been studied. Moreover, the researchers have expanded the analysis beyond growth prospects and analyzed the possible restraining factors to the growth of the Stem Cell Assay Market, thus enabling market players to foresee the likely challenges and emerge successful through the forecast period 2020-2027.

In the market segmentation by manufacturers, the report covers the following companies:

Merck & Co., Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega Corporation, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne Corporation, STEMCELL Technologies, and Cellular Dynamics International.

The report covers exhaustive analysis on:

Stem Cell Assay Market Segments

Stem Cell Assay Market Dynamics

Stem Cell Assay Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies involved

Value Chain

Stem Cell Assay Market regional analysis includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Europe (Turkey, Germany, Russia, United Kingdom, Italy, France, etc.)

North America (United States, Mexico and Canada).

South America (Brazil etc.)

Middle East and Africa (GCC countries and Egypt).

The report assesses key players in the Stem Cell Assay Market, studying their services, strategies, landmarks, growth plans, and recent developments. By studying multiple organizations covering small, medium, and large players the report enables emerging players to equip themselves with knowledge of competition scenarios. The most critical aspect in the competitive landscape individual growth strategy is studied extensively by dwelling into the foregoing growth trajectory of the organization. Moreover, the study paints a picture of the individual standpoints of the players in the years to come, considering the drivers and trends.

To breakdown the vast study that spreads through geographies, products, and end-use segments, among other market-specific segments, the authors present CAGR (Compound Annual Growth Rate) of each segment throughout the years of forecast. CAGR is a simplistic representation of growth that clearly projects which segment registered the highest/least growth through the forecast period 2020-2027. Moreover, each segment is analyzed on the basis of volume and volume, also projected with year-on-year growth and CAGR.

Researchers also present production and consumption analysis, key findings, important suggestions and recommendations, and other aspects, thus offering a comprehensive picture of the Stem Cell Assay Market to bolster market players in planning their strategies in the years to come.

Get Full Report Access at:https://www.coherentmarketinsights.com/ongoing-insight/stem-cell-assay-market-1632

Important Questions Answered

What is the growth potential of the Stem Cell Assay market?

Which company is currently leading the Stem Cell Assay market? Will the company continue to lead during the forecast period 2020-2027?

What are the top strategies that players are expected to adopt in the coming years?

Which regional market is anticipated to secure the highest market share?

How will the competitive landscape change in the future?

What do players need to do to adapt to future competitive changes?

What will be the total production and consumption in the Stem Cell Assay Market by 2027?

Which are the key upcoming technologies? How will they impact the Stem Cell Assay Market?

Which product segment is expected to show the highest CAGR?

Which application is forecast to gain the biggest market share?

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! @ https://www.coherentmarketinsights.com/insight/request-discount/1632

Highlights of TOC:

Overview: Presents a broad overview of the Stem Cell Assay Market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Stem Cell Assay Market.

Product Segments: Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Stem Cell Assay Market.

Geographical Segments: Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles: Leading and emerging players of the Stem Cell Assay Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Why Do Companies Trust CMI?

24/7 customer service available for clients in different time zones

High-quality market reports available at affordable prices

A methodical and systematic market research process

Thorough understanding of the current trends in the market research industry

Our analytical insights have facilitated the growth of multiple companies worldwide

Contact us for any query or to get a personalized [emailprotected]: https://www.coherentmarketinsights.com/insight/request-customization/1632

NOTE:Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

providesCOVID-19 Vaccine Trackerfor all the latest updates about COVID-19 Vaccine.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

Mr. ShahCoherent Market Insights1001 4th Ave,#3200Seattle, WA 98154Tel: +1-206-701-6702Email: [emailprotected]

Here is the original post:
Impact Analysis of Covid-19 On Global Stem Cell Assay Market Continues to Expand to Support Development and Top Players: Merck & Co., Thermo...

Latest updated Report gives analysis of Cell Expansion market overview, scope, market risks, market driving force and market opportunities. Cell Expansion competitive situation, sales, revenue and global market share of top manufacturers working in Cell Expansion industry are analyzed clearly by landscape contrast

The Global Cell Expansion Market divides the industry on the basis of the regions by growth, product types and applications, over the forecast period (2020-2027) of the Cell Expansion market. It analyzes every majorfacts of the global Cell Expansion by specifications of the product, restraints, challenges, andgrowth opportunities. Company profiles of the major leading player with Cell Expansion investment forecast, latest technology trends,and future forecast. Detailed global understanding of the Cell Expansion market based on present and future size(revenue) and Cell Expansion market prediction plot in the form of a list of charts and tables, pie-charts to assist aspirants and major market players in making significant and growing choices.

Download Free Sample Pdf Report @ https://www.globalmarketers.biz/report/chemicals-and-materials/2015-2027-global-cell-expansion-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/145834#request_sample

The research mainly covers Cell Expansion market in North America (United States, Canada and Mexico), Cell Expansion Europe industry (Germany, France, UK, Russia and Italy), Asia-Pacific (Southeast Asia, China, Korea, India and Japan), Cell Expansion South America industry (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). The Cell Expansion report also performs SWOT (Strengths, Weaknesses, Opportunities, and Threats) with XX CAGR values, and XX USD of past(2015-2019) and Cell Expansion forecast(2020-2027) on the basis of growth and market condition following with the size of Cell Expansion market.

The Global Cell Expansion market reportcomprises variouskey manufacturers, application analysis and type analysis:

Key players of the global Cell Expansion market:

STEMCELL Technologies Inc.Lonza Group Ltd.Danaher CorporationMerck KGaAMiltenyiBiotecBecton, Dickinson and CompanyCorning, Inc.Thermo Fisher Scientific, Inc.GE HealthcareTerumo BCT

Market Segment Analysis

By Types:

ReagentMediaFlow CytometerCentrifugeBioreactor

By Applications:

Regenerative Medicine & Stem Cell ResearchCancer & Cell-based Research

InquiryHere For More Details https://www.globalmarketers.biz/report/chemicals-and-materials/2015-2027-global-cell-expansion-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/145834#inquiry_before_buying

Segments of the Cell Expansion Report:

Global Cell Expansion market report figure out a detailed analysis of key Cell Expansion market players by referencing their company profiles, supply/demand study, sales margin, gross margin and year to year revenue to have Cell Expansion industry better share over the globe. Cell Expansion market report also includes development.

The Global Cell Expansion industry research report analyses the supply, sales, production, and market status comprehensively. manufacturing market shares and sales market shares are analyzed along with the analysis of capacity, production, sales, and revenue.

Table Of Content Described:

1. Cell Expansion Industry Synopsis

2. Global Cell Expansion Market Size by Segmentation (2020-2027)

3. Cell Expansion Leading Manufacturers Company Profiles

4. Global Cell Expansion Market Competitive Study by Players

5. US Cell Expansion Market Development Status and Overview

6. Europe Cell Expansion Market Improvement Status and Overview

7. Africa Cell Expansion Market Development Status and Overview

8. South-America Cell Expansion Market Improvement Status and Overview

9. Asia-pacific Cell Expansion Market Development Status and Overview

10. Southeast Asia Cell Expansion Improvement Status and Overview

11. Cell Expansion Market Forecast by Regional Analysis, And By Segmentation (2020-2027)

12. Dynamics of Cell Expansion Market

13. Cell Expansion Market Growth Factors Study

14. Research Conclusions

15. Appendix

Explore Detailed Information, Table Of Content https://www.globalmarketers.biz/report/chemicals-and-materials/2015-2027-global-cell-expansion-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/145834#table_of_contents

Continue reading here:
Global Cell Expansion Market Size 2020 | Growth Opportunities, Top Leaders, Revenue, Regional Overview and Forecast to 2027 - PRnews Leader

New York, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Primary Cells Market Research Report by Origin, by Cell Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05987887/?utm_source=GNW

The Global Primary Cells Market is expected to grow from USD 925.79 Million in 2019 to USD 1,733.95 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 11.02%.

Market Segmentation & Coverage: This research report categorizes the Primary Cells to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Origin, the Primary Cells Market studied across Animal Primary Cells and Human Primary Cells.

Based on Cell Type, the Primary Cells Market studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.

Based on End-user, the Primary Cells Market studied across Life Science Companies and Research Institutes.

Based on Geography, the Primary Cells Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Primary Cells Market including AcceGen, Allcells, American Type Culture Collection, Axol Bioscience Ltd., BioIVT, Biopredic International, BPS Bioscience, Inc., Cell Biologics, Inc., Corning Incorporated, Creative Bioarray, Epithelix SRL, Ixcells Biotechnologies, Lonza Group AG, Merck KGaA, Neuromics, Ppa Research Group, Inc., Promocell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Primary Cells Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Primary Cells Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Primary Cells Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Primary Cells Market? 4. What is the competitive strategic window for opportunities in the Global Primary Cells Market? 5. What are the technology trends and regulatory frameworks in the Global Primary Cells Market? 6. What are the modes and strategic moves considered suitable for entering the Global Primary Cells Market?Read the full report: https://www.reportlinker.com/p05987887/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Continue reading here:
Primary Cells Market Research Report by Origin, by Cell Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19 - GlobeNewswire

MarketsandResearch.biz presents Global Cell and Gene Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which shows the most recent industry chain structure and complete analysis of the market. The report offers detailed information on enterprises on a global and regional level through an all-inclusive analysis and insights into developments affecting businesses. The report covers the market landscape and its growth prospects over the coming years. Leading companies effective in this market are discussed further. The report calculates the market size and considers the revenue generated from the sales of Cell and Gene Therapy globally. The research accommodates an entire overview of the market, including the market share, and the projection of this global market, within a specific interval of time.

The report contains critical information on the market which will assist the industry players in making informed business move. The report is segmented by application/ end-user, product type, and geologies. This report will help you to make informed decisions, understand opportunities, plan new projects, analyze drivers and restraints, and give you a vision of the industry forecast (2020-2025). The report further explains the competitive backdrop of key players in the market as well as their product portfolio and business strategies. It offers an investigation of the global Cell and Gene Therapy industry in terms of consumption and production.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/110107

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

Market Status:

The market report provides the major growth factors and limitations that notably affect market growth. The report studies the data about the past and present status of the global Cell and Gene Therapy market globally. The upcoming economic fluctuations related to the current market growth pattern of the market are investigated. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

The market competition by top manufacturers/key player profiled: Amgen Inc., Novartis AG, Fibrocell Science, Inc., bluebird bio, Inc., Kolon TissueGene, Inc., Dendreon Pharmaceuticals LLC., Organogenesis Holdings Inc., Kite Pharma, Inc., Human Stem Cells Institute, Orchard Therapeutics plc., Spark Therapeutics, Inc., Pfizer, Inc., Vericel Corporation, Sibiono GeneTech Co. Ltd.,, RENOVA THERAPEUTICS, ViroMed Co., Ltd., Shanghai Sunway Biotech Co., Ltd.,

The report conjointly categorizes the market into main product kind: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology, Other Therapeutic Classes

The report splits the market into main applications: Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Contract Research Organizations (CROs), Hospital, Others

The report offers an in-depth assessment of the growth and other aspects of the market in important regions, including: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

The conclusion contains the evaluation of the global Cell and Gene Therapy market through multiple classifications and provides thorough information about the upstream raw materials, downstream buyers, and distribution channels established by the various competitors. More importantly, a study of recent market trends, drivers, challenges, and opportunities shaping the profitability graph of the industry are presented further in the report.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/110107/global-cell-and-gene-therapy-market-2020-by-company-regions-type-and-application-forecast-to-2025

Key Pointers:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Read the original here:
Global Cell and Gene Therapy Market 2020 Key Drivers and Challenges, Opportunities and Forecast Insights by 2025 - KYT24

Kenneth Research has published a detailed report on Asset Tracking and Inventory Management Solutions Market which has been categorized by market size, growth indicators and encompasses detailed market analysis on macro trends and region-wise growth in North America, Latin America, Europe, Asia-Pacific and Middle East & Africa region. The report also includes the challenges that are affecting the growth of the industry and offers strategic evaluation that is required to boost the growth of the market over the period of 2019-2026.

Request To Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10307133

The report covers the forecast and analysis of the Asset Tracking and Inventory Management Solutions Market on a global and regional level. The study provides historical data from 2015 to 2019 along with a forecast from 2019-2026 based on revenue (USD Million). In 2018, the worldwide GDP stood at USD 84,740.3 Billion as compared to the GDP of USD 80,144.5 Billion in 2017, marked a growth of 5.73% in 2018 over previous year according to the data quoted by International Monetary Fund. This is likely to impel the growth of Asset Tracking and Inventory Management Solutions Marketover the period 2019-2026.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Market: OverviewInventory management systems are likely to help many businesses to administer stocks of expendable commodities across different surroundings. Such solutions are likely to influence supplier data, for instance, the available supply of parts and materials cost, & buyer data such as sales history, which helps to enhance the forecasting and planning for sales and production.

The rising need for a solution to sustain the organizations assets and stock pushes monitoring and inventory management solutions globally. Various business organisations, sectors and government facilities are implementing strategies for monitoring and maintaining inventories to reduce human effort, improve product life cycle management, reduce operating costs, and others. Such benefits allow companies to increase their profitability.

Scope of the ReportThe global asset tracking and inventory management solutions market is broadly segmented by component, application, and industry. Hardware revenue contribution is mainly due to significant deployment of inventory management and asset tracking solutionsby businesses due to increasing demand for proper inventory management needs. However, the software segment is expectedto contribute significantly over the forecast period.

Market Segmentationby Asset Type:Electronics AssetsReturnable Transport AssetsIn-Transit EquipmentManufacturing AssetsPersonnel/ Staff

by Function:Location/Movement TrackingCheck-In/Check-OutRepair & Maintenance

by Solution:Radio Frequency Identification (RFID)Real-Time Location System (RTLS)Global Positioning System (GPS)

by Industry:RetailHealthcareTransportation and LogisticsHospitality

By Regional AnanlysisNorth America*U.S.*Canada

Europe*Germany*UK*France*Italy*Spain*Belgium*Russia*Netherlands*Rest of Europe

Asia-Pacific*China*India*Japan*Korea*Singapore*Malaysia*Indonesia*Thailand*Philippines*Rest of Asia-Pacific

Latin America*Brazil*Mexico*Argentina*Rest of LATAM

Middle East & Africa*UAE*Saudi Arabia*South Africa*Rest of MEA

Enterprises are adopting asset tracking and inventory management solutions in order to increase revenue and to overcome the challenges concerning the loss faced due to the mismanaged inventories. Some of the prominent players identified in the asset tracking and inventory management solutions market and profiled in the study include ASAP Systems, Chekhra Business Solutions, Datalogic S.P.A., EMS Barcode Solutions, LLC, Epicor Software Corporation, GigaTrak, JDA Software, Lowry solutions Inc., Microsoft Corporation, Oracle Corporation, RedBeam, Inc., Honeywell International Inc., SAP SE, Stanley Black & Decker, Inc., Tenna, LLC, Trimble Inc., TVL, Inc. (WiseTrack), Ubisense Group PLC, Wasp Barcode Technologies, Inc., Zebra Technologies Corporation, Jolly Technologies, Brilliant Info Systems Pvt. Ltd. and Windward Software. Key players are adopting different strategies such as mergers and acquisitions, product launch, and R& D focus to enhance the customer base. For instance, in 2017, Jolly Technologies announced the public release of Version 8 of its product line including Lobby Track, ID Flow,Asset Track, Eventleaf Desktop, and Label Flow.

Click Here to Download Sample Report >>https://www.kennethresearch.com/sample-request-10307133

Competitive Analysis:The Asset Tracking and Inventory Management Solutions Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included in this report with Porters five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Key points covered in this report: The historical and current data is provided in the report based on which the future projections are made and the industry analysis is performed. The import and export details along with consumption value and production capability of every region is mentioned in the report. Porters five forces analysis, value chain analysis, SWOT analysis are some additional important parameters used for the analysis of market growth. The report provides the clients with the facts and figures about the market on the basis of evaluation of the industry through primary and secondary research methodologies.

The Asset Tracking and Inventory Management Solutions Market report highlight the economy, past and emerging trend of industry, and availability of basic resources. Furthermore, the market report explains development trend, analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Asset Tracking and Inventory Management Solutions Market before evaluating its possibility.

About Kenneth Research:Kenneth Research is a reselling agency which focuses on multi-client market research database. The primary goal of the agency is to help industry professionals including various individuals and organizations gain an extra edge of competitiveness and help them identify the market trends and scope. The quality reports provided by the agency aims to make decision making easier for industry professionals and take firm decisions which helps them to form strategies after complete assessment of the market. Some of the industries under focus include healthcare & pharmaceuticals, ICT & Telecom, automotive and transportation, energy and power, chemicals, FMCG, food and beverages, aerospace and defense and others. Kenneth Research also focuses on strategic business consultancy services and offers a single platform for the best industry market research reports.

Contact UsKenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0911Upcoming Security Software MarketContraceptives MarketIntragastric Balloon MarketStem Cell Banking MarketOrphan Drugs MarketConductive Rubber MarketCognitive Security MarketCell-free DNA Testing MarketRigid Foam Insulation MarketSpine Orthopaedic Devices MarketSilicone Sealant Market

Read the original:
Asset Tracking and Inventory Management Solutions Market outlook by industry size share revenue regions and top key players analysis - The Think...

CMR announced that its published a business report namely Global DAPT Market by Size, Share, Growth, Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide DAPT Market.

We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global DAPT market. Leading players of the global DAPT Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served.

This Press Release will help you to understand the Volume, growth with COVID19 Impact Analysis. Click HERE To get SAMPLE PDF (Including TOC, Table & Figures) at: @ https://chronicalmarketresearch.com/request-for-sample-report/23322

The DAPT Market report is a compilation of first-hand information, qualitative and competitive assessment industry analysts, inputs from industry experts, and industry participants across the value chain. The research report market provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments, trending Key Factors, and geographies.

The **Key Manufacturers** covered in this Report:-

The major vendors covered:

R&D Systems

Abcam

Stemgent

Cayman Chemical

Santa Cruz Biotechnology

STEMCELL Technologies

Alfa Chemistry

Anward

Race Chemical

Glentham Life Sciences

AbMole Bioscience

Aurum Pharmatech LLC

Tocris Bioscience

Enzo Life Sciences

The chapter on competitive landscape provides information about key company overview, global presence, sales and revenue generated, market share, prices, and strategies used.

Request Discount About This Report @ https://chronicalmarketresearch.com/discount-request-on-report/23322

The Coronavirus (COVID-19) pandemic has affected every aspect of life worldwide. It has forced various industries to re-evaluate their strategies and adopt new ones to sustain during these trying times. The latest report includes the current COVID-19 impact on the market.

Our analysts engage in extensive primary and secondary research to cull out in-depth and authentic information. Primary research includes gathering information from official government and company websites, journals, and reports. Contact our sales team who will guarantee you to get a customized report that suits your specific needs.

Segment by Type, the DAPT market is segmented into

Low Purity(Below 97%)

Purity(Above 97% and Below 99%)

High Purity(Above 99%)

Others

Segment by Application, the DAPT market is segmented into

Medical Treatment

Bioscience Research

Others

Regional and Country-level Analysis

The DAPT market is analysed and market size information is provided by regions (countries).

The key regions covered in the DAPT market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

Request For Customization About This Report @ https://chronicalmarketresearch.com/request-for-customization/23322

Which Market Factors Are Explained In The Report?

**Key Strategic Developments**: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

**Key Market Features**: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics, and their latest trends, along with pertinent market segments and sub-segments.

**Analytical Tools**: The Global DAPT Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

The DAPT Market Report Provides:

The main questions answered in the report:

In this study, the years considered to estimate the market size of the DAPT Market are as follows:

History Year: 2013-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2020 to 2027

You can also request custom information like chapter-wise or specific region-wise study as per your interest.

Contact Us

Chronical Market Research,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.chronicalmarketresearch.com

About Us

At Chronical Market Research, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Chronical Market Research an asset to your business.

Read more:
DAPT Market to Witness Increase in Revenues by 2020-2028 - The Think Curiouser